Testing For Minimal Residual Disease In CLL

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Testing For Minimal Residual Disease In CLL

CAR T-cell Therapy in CLL (chronic lymphocytic leukemia): Navigating the Landscape and Looking Ahead with Catherine Coombs, MD

Nitin Jain, MD Challenging case involving advanced B-cell lymphoblastic leukemia (BLL) from the CAR-T and Bispecifics Conference [2024]

Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates

Testing For Minimal Residual Disease In CLL

Related Posts

CAR T-cell Therapy in CLL (chronic lymphocytic leukemia): Navigating the Landscape and Looking Ahead with Catherine Coombs, MD

Nitin Jain, MD Challenging case involving advanced B-cell lymphoblastic leukemia (BLL) from the CAR-T and Bispecifics Conference [2024]

Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates